Novavax, Inc. NVAX
Novavax, Inc. (Nasdaq: NVAX) is a GI/hepatology drug developer. Its lead program, Clostridioides difficile colitis vaccine, is in Pre-clinical for Clostridioides difficile colitis. Its next catalyst on record is Manufacturing technology transfer to Sanofi for Nuvaxovid™: Completion of tech transfer (triggers $75M milestone) (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Manufacturing technology transfer to Sanofi for Nuvaxovid™ — Completion of tech transfer (triggers $75M milestone) (H1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Clostridioides difficile colitis vaccine | Clostridioides difficile colitis | protein/peptide | Pre-clinical |
| Varicella-zoster virus (shingles) vaccine | Shingles | protein/peptide | Pre-clinical |
| Respiratory syncytial virus vaccine | RSV | protein/peptide | Pre-clinical |
Recent results and decisions
- Oct 28, 2026started Sanofi initiated Phase 3 trial of influenza-COVID-19 combination vaccine using Novavax's Nuvaxovid in adults aged 60 and older in Europe.
Sanofi's Phase 3 trial, being conducted in Europe, is assessing the safety and immunogenicity of Nuvaxovid in combination with Sanofi's marketed Efluelda/Fluzone® High-Dose vaccine in adults aged 60 and older.
Filing - Oct 28, 2026started Sanofi initiates Phase 3 trial of influenza-COVID-19 combination vaccine using Novavax's Nuvaxovid in adults aged 60 and older in Europe.
The Phase 3 trial, being conducted in Europe, is assessing the safety and immunogenicity of Nuvaxovid in combination with Sanofi's marketed Efluelda/Fluzone High-Dose vaccine in adults aged 60 and older.
Filing - Oct 28, 2026started Sanofi has initiated a Phase 3 trial in Europe of an influenza-COVID-19 combination vaccine using Novavax's Nuvaxovid in adults aged 60 and older, triggering a $125 million milestone payment to Novavax.
The combination vaccine candidate evaluated in this trial pairs Sanofi's leading high-dose flu vaccine with Novavax's differentiated COVID-19 vaccine.
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.